ENB is developing small molecule inhibitors of a novel pathway to treat melanoma and other cancers.

Our story

Almost 20 years ago, our team wanted to discover why melanoma cells travel away from the skin to distant sites in the body. We discovered that melanoma spreads through the body because a switch that should only be turned on in the developing embryo gets turned back on in melanoma patients. This switch tells melanoma cells to leave the skin and travel to distant sites, especially the brain. It also tells many different types of cancer  cells to multiply without stopping. Our therapies turn off this switch, stopping the cancer cell in its tracks and causing it to die. They also stimulate the body’s immune system to attack and kill the tumors. Our therapies have shown efficacy in preclinical studies for melanoma, glioblastoma, squamous cell carcinoma and ovarian cancer. Our therapies should also help patients with cancers that have spread to the brain as well as pancreatic cancer.  We have developed a simple and cost effective screening test to help determine those most likely to respond to our treatments. It is now time to bring these agents to those in need.

ETBR Blockers
Our target, the endothelin B receptor (ETBR), has been linked to melanoma and other cancers in over 200 peer-reviewed publications. It causes uncontrolled cancer growth, drives cancers to spread through the body and prevents the immune system from detecting and killing cancer cells.  However no drug specifically blocking the ETBR has ever been brought to market or even tested in clinical trials for cancer. Drugs that blocked other receptors in the same family failed in clinical trials for cancer because unlike our therapies, they actually prevent the immune system from killing cancer cells. It is now time to block this receptor with the right therapy to provide a solution to those with few or no therapeutic options.

Our lead product ENB-001 specifically blocks the ETBR and is proven to help otherwise ineffective immunotherapy to kill cancer cells. It has an established safety profile in humans and unlike approved drugs on the market, is anticipated to stimulate the immune system to only target and kill cancer cells. Currently approved cancer immunotherapies are associated with significant toxicity including autoimmune phenomena, the development of new skin cancers, including new melanomas, and even fatality. Our therapies have also demonstrated efficacy in preclinical models at treating melanoma, glioblastoma, squamous cell carcinoma of the head and neck, ovarian cancer and is anticipated to work for pancreatic cancers among others.

Using cutting edge technology, we have developed a proprietary nanoparticle formulation that will enhance efficacy and is anticipated to selectively concentrate in cancerous tissues, sparing exposure to normal tissue and enhancing the safety profile.

We have the key to unlock the full therapeutic potential of immuno-oncology platforms

Our products  as first-line combination therapy with immune-oncology agents to create a new and superior standard of care that blocks key mechanisms of drug resistance, stimulates the body’s immune system to fight cancer and prevents cancer from spreading through the body

Our team

Sumayah Jamal, MD-PhD, President, Co-founder, Chief Scientific Officer

  • Research career spanning 30+ years
  • Co-inventor on first patents field covering the endothelin B receptor as a therapeutic target of cancer.
  • The work she conducted as a Principal Investigator at NYU School of Medicine serves as the foundation for the drug development programs of ENB Therapeutics.
  • Recipient of the American Academy of Dermatology Young Investigator Award.
  • The American Academy of Dermatology Everett C. Fox M.D. Award.
  • The Pan American Society for Pigment Cell Research Young Investigator Award.

Sandy Harm,  Chief Business Officer

  • 24 years senior exec at Merck
  • Pharmaceutical and healthcare leader with extensive experience in Research and Development Operations from bench to commercialization
  • Strong background in clinical research, Investigator Initiated Studies, customer interactions, project management, launch planning, medical affairs strategy, operations and planning, compliant business practices and sales.
  • Broad based disease area experience, with particular expertise in Oncology (10+years), and 15+ years customer interactions.
  • Oversaw launch and development of Keytruda

Robert Schneider, PhD, Co-founder, Chair of Scientific Advisory Board
Associate Dean, Office of Therapeutics Alliances, NYUMC, Associate Director for Translational Research, NYU Cancer Institute, Director, Breast Cancer Program, Albert Sabin Professor of Molecular Pathogenesis

  • Senior Principal Investigator, Oversees Drug Discovery and Development programs at NYUMC.
  • Strong track record of licensing inventions and intellectual property to industry and investment partners
  • Co-founder of numerous successful biopharma start up companies including ImClone, Canji and PTC Therapeutics

For Investors


Preview our investor deck here